Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
9,738,748
-
Share change
-
+237,792
-
Total reported value
-
$12,466,903
-
Put/Call ratio
-
204%
-
Price per share
-
$1.28
-
Number of holders
-
71
-
Value change
-
-$1,711,528
-
Number of buys
-
41
-
Number of sells
-
41
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2024
As of 30 Jun 2024,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
71 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,738,748 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, FMR LLC, VANGUARD GROUP INC, BlackRock Inc., BNP PARIBAS FINANCIAL MARKETS, GEODE CAPITAL MANAGEMENT, LLC, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, NORTHERN TRUST CORP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and WELLS FARGO & COMPANY/MN.
This page lists
71
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.